Celltrion: 주요사항보고서(자기주식취득결정)
AI reading
★★★★ Bullish · Buyback
주가 안정 및 주주가치 제고를 위한 자기주식 취득 및 전량 소각 계획
Key figures: 취득예정금액 1,000억
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Celltrion
- 09.23 ★★★ Zymfentra US Phase 3 clinical trial approval (rheumatoid arthritis)
- 09.23 ★★ Large Shareholding Report (General)
- 09.21 ★★★ Darzalex biosimilar EU Phase 3 clinical trial approval
- 09.16 ★★ Cancellation of treasury shares for stock price stabilization and shareholder value enhancement
- 09.07 ★★★ Keytruda biosimilar US Phase 3 clinical trial amendment approval
- 09.07 ★★★ Darzalex biosimilar Korea Phase 3 clinical trial amendment approval
For information only. Not investment advice.